G1 Therapeutics

Pipeline Progress: Over 25 New Therapies in Development for Metastatic Liver Cancer

2 months ago

• DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options. • Several promising clinical trials are underway in 2025, including studies evaluating novel combinations such as AK104 plus lenvatinib, tislelizumab with lenvatinib, and triplet therapy of nivolumab, relatlimab and bevacizumab. • Key emerging therapies include exoASO-STAT6 targeting tumor-associated macrophages, STP705 dual TGF-ß1/COX-2 inhibitor, and ONCR-177, an oncolytic viral immunotherapy expressing five transgenes to fight tumors through multiple mechanisms.

DelveInsight Report: Over 50 Pipeline Drugs in Development for Urothelial Carcinoma Treatment

4 months ago

• DelveInsight's latest pipeline analysis reveals 40+ pharmaceutical companies actively developing 50+ therapeutic candidates for urothelial carcinoma treatment, indicating robust research activity in this space. • Major pharmaceutical companies including AstraZeneca, Seagen, and Janssen are advancing promising therapies, with notable candidates like disitamab vedotin and cetrelimab in late-stage development. • Recent clinical trials include Seagen's Phase 2 study of disitamab vedotin with pembrolizumab, and Roche's Phase 1b/II umbrella study investigating multiple combination therapies for advanced urothelial carcinoma.

mTNBC Pipeline Shows Promise with Novel Therapies in Clinical Trials

6 months ago

• The mTNBC pipeline includes over 12 drugs from 10+ companies, targeting novel approaches to improve treatment outcomes for this aggressive breast cancer. • Trilaciclib, a CDK4/6 inhibitor by G1 Therapeutics, is in Phase III trials to preserve bone marrow and immune function during chemotherapy in mTNBC patients. • Olinvacimab, an anti-angiogenic antibody by PharmAbcine/Merck, is in Phase II trials, blocking the VEGF/VEGFR2 pathway to inhibit tumor growth and metastasis. • Emerging therapies focus on intravenous, subcutaneous, and oral routes of administration, with molecule types including monoclonal antibodies and small molecules.

Robust Clinical Trial Pipeline Fuels Hope for Renal and Breast Cancer Advances

8 months ago

• The renal cancer clinical trial pipeline is robust, with over 70 companies developing more than 75 therapies, including novel immunotherapies and targeted agents. • Breast cancer research is also thriving, with over 100 companies exploring 120+ new drugs, such as antibody-drug conjugates and PARP inhibitors, in clinical trials. • Recent FDA actions, including Fast Track and Breakthrough Therapy designations, highlight the potential of emerging therapies for both renal and breast cancer. • Advances in diagnostics, such as PET imaging agents for clear cell renal cell carcinoma, are also contributing to improved management of these diseases.

Pharmacosmos Completes Strategic Acquisition of G1 Therapeutics in Multi-Million Dollar Deal

8 months ago

• Danish pharmaceutical company Pharmacosmos has finalized its acquisition of US-based G1 Therapeutics, gaining ownership of the cancer drug Cosela in a deal valued at over half a billion kroner. • The acquisition represents a significant expansion for Pharmacosmos, traditionally focused on iron deficiency treatments, into the oncology market with an established commercial product. • Company executives indicate they will focus on integration over the next six months, with potential for additional acquisitions in the longer term but not immediately.

Pharmacosmos Group Acquires G1 Therapeutics for $405 Million to Expand COSELA Access for Cancer Patients

9 months ago

• Pharmacosmos Group has successfully completed its acquisition of G1 Therapeutics for $7.15 per share, representing a 68% premium to G1's closing price before announcement and a total equity value of approximately $405 million. • The acquisition brings COSELA (trilaciclib), the first and only FDA-approved therapy for chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer patients, into Pharmacosmos' portfolio of hematology and supportive care products. • Pharmacosmos plans to leverage its global commercial presence and expertise in hematology to expand COSELA's availability beyond the US and China markets, with plans to pursue registration in the UK and EU.